Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03308591
Other study ID # CSEM GOG-005B
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 1, 2016
Est. completion date December 31, 2020

Study information

Verified date February 2019
Source Huazhong University of Science and Technology
Contact Ding Ma, MD PhD
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In recent years, the patients with IB2 and IIA2 stage cervical cancer are still treated with radiotherapy and chemotherapy based treatment, but the radiotherapy will severely damage the function of ovary, cause endocrine dyscrasia and the sexual function of vagina. So we want to study whether neoadjuvant chemotherapy without radiotherapy will achieve the same outcome compared with traditional therapy including radiotherapy. So we randomly divide IB2 and IIA2 stage cervical cancer patients into two groups. The neoadjuvant chemotherapy group will receive two courses of chemotherapy basically composed of platinum, and then undergo surgery, after that, doctors will add more courses of chemotherapy according to the situations of the patients, including whether the patients have the adverse prognostic factors. The control group will undergo surgery directly, and then receive chemotherapy and radiotherapy at the same time. Then we will compare the outcomes of these two groups, and analyze the therapeutic effect, the impact on survival rate and the effect on improving the living quality of patient from two groups. All the outcomes will be fed back to clinical doctors and instruct them to choose better treatment for patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date December 31, 2020
Est. primary completion date April 30, 2019
Accepts healthy volunteers No
Gender Female
Age group N/A to 65 Years
Eligibility Inclusion Criteria:

- clinical diagnosis IB2 or IIA2 stage cervical cancer;

- age less than or equal to 65 years old;

- laboratory examination results: WBC = 4*10^9/L, NEU = 20*10^9/L, PLT = 80*10^9/L, serum bilirubin = 2 multiples of the upper normal limit, aminopherase = 2 multiples of the upper normal limit. BUN = normal limit, CR = normal limit;

- KARNOFSKY score = 60;

- No prior treatment;

- pathological diagnosis before surgery is invasive squamous cell carcinoma of cervix;

- well-compliance and willing to keep in touch;

- willing to participate in this study, and sign the informed consent;

Exclusion Criteria:

- participate in other drug clinical trials at the same time;

- respiratory depression, airway obstruction and hypoxia;

- heart diseases (cardiac function at grade II, III or above);

- hematological diseases;

- obvious dysfunction of liver and kidney (above 3 multiples of the upper normal limit);

- a history of brain dysfunction;

- unable to receive surgery and/or unsuitable for radiotherapy or chemotherapy;

- drug abuse or a history of drug abuse;

- unable or unwilling to sign informed consents;

- unable or unwilling to follow the protocols;

Study Design


Intervention

Drug:
NACT
Platin based chemotherapy
Procedure:
RT+PLND
radical hysterectomy+pelvic lymphadenectomy
Drug:
Adjuvant chemotherapy
Platin based chemotherapy

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Huazhong University of Science and Technology

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other chemotherapy- and radiotherapy- related adverse effects respectively in two groups Up to 3-year
Primary disease-free survival (DFS) of the neoadjuvant chemotherapy Group DFS was definite as the time from randomization to disease recurrence (including death from recurrence if it was the first manifestation of recurrence), death without recurrence. Up to 3-year
Secondary DSF of the synchro-chemoradiotheraphy group Up to 3-year
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A